Dept. of Emergency Medicine, Helsingborg General Hospital, Helsingborg, Sweden; Dept. of Clinical Sciences Lund, Clinical Sciences Helsingborg, Lund University, Lund, Sweden.
Dept. of Clinical Sciences Lund, Clinical Sciences Helsingborg, Lund University, Lund, Sweden.
Epilepsy Behav. 2021 Jan;114(Pt A):107554. doi: 10.1016/j.yebeh.2020.107554. Epub 2020 Dec 7.
To explore associations between the characteristics of people with epilepsy (PWE) and their attitudes toward generic substitution of antiseizure drugs (ASDs) in epilepsy.
This was a cross-sectional survey study directed at adults with epilepsy using selected brand drugs: Keppra®, Lamictal®, Lyrica® or Topimax®. Symptoms of anxiety and depression, sense of self-efficacy, and beliefs about medicines were assessed. Caregivers were asked to answer for persons with intellectual or communicative difficulties.
The total response rate was 41% (n = 178). Almost half (46%) of subjects stated that they would oppose generic substitution (Gen-NEG) if suggested by their neurologist, while 71% would worry about adverse effects and/or increased seizure frequency after a putative switch. Age ≥50 increased the odds of being Gen-NEG (adjusted OR: 2.20, 95% CI: 1.18-4.11). Negative associations with both Gen-NEG and worriers were found for education level of high-school diploma or above, employment/studies, and prior experience of generic ASD switch. The proportion of worriers was much higher among caregivers (21/22) compared to subjects with epilepsy (106/156).
High proportions of PWE express concerns regarding generic substitution of ASDs. The elderly and caregivers seem to express particular concerns. Identifying ways to diminish negative outcomes and worries in connection with a switch is an important future field of research in order to ensure high quality, cost-effective health care for the most vulnerable people in our societies.
探讨癫痫患者(PWE)的特征与其对癫痫抗癫痫药物(ASD)仿制药替代态度之间的关系。
这是一项针对使用选定品牌药物(开浦兰、拉莫三嗪、乐瑞卡或妥泰)的成年癫痫患者的横断面调查研究。评估了焦虑和抑郁症状、自我效能感以及对药物的信念。对于有智力或沟通困难的患者,要求其照顾者回答问题。
总应答率为 41%(n=178)。近一半(46%)的受试者表示,如果他们的神经科医生建议,他们会反对仿制药替代(Gen-NEG),而 71%的人会担心在假定的转换后出现不良反应和/或癫痫发作频率增加。年龄≥50 岁会增加反对仿制药替代的几率(调整后的 OR:2.20,95%CI:1.18-4.11)。与 Gen-NEG 和担忧者均呈负相关的是,具有高中或以上学历、就业/学习和先前经历过 ASD 仿制药转换。与癫痫患者(106/156)相比,照顾者中担忧者的比例(21/22)高得多。
相当比例的 PWE 对 ASD 仿制药替代表示担忧。老年人和照顾者似乎表达了特别的担忧。确定如何减少与转换相关的负面结果和担忧是未来一个重要的研究领域,以确保我们社会中最脆弱人群获得高质量、具有成本效益的医疗保健。